-
2025-522791-92-00
5
Neoplasm Metastasis
-
2025-523389-26-00
5
Relapsed/refractory primary central nervous system lymphoma
-
2025-523460-21-00
4
Metastatic breast cancer
-
2025-523461-17-01
5
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2025-523555-66-00
5
Myelofibrosis
-
2025-524077-16-00
4
metastatic urothelial carcinoma
-
2025-524308-31-00
4
Acute myeloid leukemia
-
2025-524843-11-00
4
Non-Small Cell Lung Cancer
-
2024-518858-17-00
4
2026-05-22
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
-
2025-522107-18-00
4
2026-05-19
Locally advanced or metastatic Non-Small Cell Lung Cancer
-
2025-522981-61-00
4
2026-05-19
endometrial cancer
-
2024-511496-14-00
5
2026-05-14
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-523742-27-00
9
2026-04-28
Advanced solid tumors
-
2025-523803-31-00
4
2026-04-16
Advanced non-small cell lung cancer (NSCLC)
-
2024-512248-47-00
9
2026-04-15
Non-small Cell Lung Cancer (NSCLC)
-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2025-523533-25-00
10
2026-03-26
Cancer-associated Cachexia
-
2025-521939-36-00
4
2026-03-03
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2023-508995-12-01
4
2025-12-24
Recurrent or metastatic non-small cell lung cancer (NSCLC)
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2022-503140-41-00
5
2025-12-19
Melanoma